Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2007

Stemline Therapeutics In-Licenses Oncology Compound

  • Stemline Therapeutics in-licensed the exclusive worldwide rights to SL-401, a Phase I compound directed at a cancer stem cell target from the Scott & White Cancer Research Institute/Texas A&M Health Science Center College of Medicine. SL-401 has reportedly demonstrated single agent antitumor activity in a multicenter, dose-escalation study.

    SL-401 targets the interleukin-3 receptor (IL-3R) and has been shown to impair the ability of cancer stem cells to form tumors.  IL-3R is over-expressed on multiple hematological cancers. In AML, IL-3R is over-expressed on both leukemia blasts as well as leukemia cancer stem cells.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »